Incyte INCY JAKAVI Royalty Revenues — Total revenues

Other product segments

Similar metrics at other companies

SUP

SUPNRoyalty, licensing, and other revenues — Total revenues

$29.31M+274%

GERNRoyalties — Total revenues

$66K-60.5%

LGNDRoyalties — Total revenues and income

$42.96M+56.3%

NVAXRoyalties — Total Revenue

$3.52M—

GILDRoyalty, contract and other revenues — Total revenues

$14M-74.1%

AUPHJapan — Revenue

$4.8M-23.3%

Questions, answered.

What is Incyte's JAKAVI royalty revenues — total revenues?

Incyte (INCY) reported JAKAVI royalty revenues — total revenues of $105.56M in Q1 2026.

How has Incyte's JAKAVI royalty revenues — total revenues changed year-over-year?

Incyte's JAKAVI royalty revenues — total revenues increased by 14.6% year-over-year, from $92.15M to $105.56M.

What is the long-term trend for Incyte's JAKAVI royalty revenues — total revenues?

Over 4 years (2021 to 2025), Incyte's JAKAVI royalty revenues — total revenues has grown at a 7.9% compound annual growth rate (CAGR), from $337.99M to $457.73M.

What does JAKAVI royalty revenues — total revenues mean?

This metric represents the total royalty income generated from the licensing and commercialization of a specific pharmaceutical product, typically an oral Janus kinase inhibitor. It reflects the recurring revenue stream earned by the company based on the net sales performance of the drug in international markets managed by a partner. This revenue source is a critical component of the company's diversified income model, highlighting the success of its strategic licensing agreements.